Literature DB >> 31193944

Skin surface markers for stereotactic body radiation therapy of sternal metastasis.

Hossein Hemmatazad1, Daniel Schmidhalter2, Olgun Elicin1, Daniel M Aebersold1, Evelyn Herrmann1.   

Abstract

Stereotactic body radiation therapy is an effective and safe treatment modality for bone metastasis which allows clinicians to accurately target lesions to high doses while minimizing dose to organs at risk. The commercially available CyberKnife® Xsight™ Spine Tracking System (Accuray, Inc., Sunnyvale, CA) tracks static skeletal structures and eliminates the need for implanted fiducial markers (FMs). However, the Xsight™ Spine Tracking system is not appropriate for bone metastases outside the spine, which are moving due to respiration and ,typically, FMs have to be implanted close to the lesion. These FMs will be used to track the dynamic target. For targets close to the surface, non-invasive fixation of the FMs to the patient's skin could be an option.

Entities:  

Keywords:  CyberKnife; Fiducial marker; SBRT; Skin

Year:  2019        PMID: 31193944      PMCID: PMC6545360          DOI: 10.1016/j.rpor.2019.05.005

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  11 in total

1.  Patterns of patient movement during frameless image-guided radiosurgery.

Authors:  Martin J Murphy; Steven D Chang; Iris C Gibbs; Quynh-Thu Le; Jenny Hai; Daniel Kim; David P Martin; John R Adler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-04-01       Impact factor: 7.038

Review 2.  Stereotactic body radiation therapy for non-spine bone metastases--a review of the literature.

Authors:  Gillian Bedard; Rachel McDonald; Ian Poon; Darby Erler; Hany Soliman; Patrick Cheung; Hans Chung; William Chu; Andrew Loblaw; Edward Chow; Arjun Sahgal
Journal:  Ann Palliat Med       Date:  2016-01

3.  Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution.

Authors:  Peter C Gerszten; Steven A Burton; Cihat Ozhasoglu; William C Welch
Journal:  Spine (Phila Pa 1976)       Date:  2007-01-15       Impact factor: 3.468

Review 4.  Stereotactic body radiotherapy for de novo spinal metastases: systematic review.

Authors:  Zain A Husain; Arjun Sahgal; Antonio De Salles; Melissa Funaro; Janis Glover; Motohiro Hayashi; Masahiro Hiraoka; Marc Levivier; Lijun Ma; Roberto Martínez-Alvarez; J Ian Paddick; Jean Régis; Ben J Slotman; Samuel Ryu
Journal:  J Neurosurg Spine       Date:  2017-06-09

Review 5.  Spinal metastases: From conventional fractionated radiotherapy to single-dose SBRT.

Authors:  Carlo Greco; Oriol Pares; Nuno Pimentel; Elizabeth Moser; Vasco Louro; Xavier Morales; Barbara Salas; Zvi Fuks
Journal:  Rep Pract Oncol Radiother       Date:  2015-04-18

6.  Complications associated with the percutaneous insertion of fiducial markers in the thorax.

Authors:  Nikhil Bhagat; Nicholas Fidelman; Jeremy C Durack; Jeremy Collins; Roy L Gordon; Jeanne M LaBerge; Robert K Kerlan
Journal:  Cardiovasc Intervent Radiol       Date:  2010-07-27       Impact factor: 2.740

7.  Technical note: Image guided internal fiducial placement for stereotactic radiosurgery (CyberKnife).

Authors:  Govindarajan Janardan Mallarajapatna; Sridhar Papaiah Susheela; Kumar Gangadharaiah Kallur; Nagaraj Kanakapura Ramanna; Prashant Guthlu Ramachandra; Shivakumar Swamy Shivalingappa
Journal:  Indian J Radiol Imaging       Date:  2011-01

Review 8.  The role of radiation therapy in bone metastases management.

Authors:  Francesca De Felice; Andrea Piccioli; Daniela Musio; Vincenzo Tombolini
Journal:  Oncotarget       Date:  2017-04-11

Review 9.  Bone Metastases: An Overview.

Authors:  Filipa Macedo; Katia Ladeira; Filipa Pinho; Nadine Saraiva; Nuno Bonito; Luisa Pinto; Francisco Goncalves
Journal:  Oncol Rev       Date:  2017-05-09

10.  Safety and efficacy of ultrasound-guided fiducial marker implantation for CyberKnife radiation therapy.

Authors:  Jae Hyun Kim; Seong Sook Hong; Jung Hoon Kim; Hyun Jeong Park; Yun-Woo Chang; A Ram Chang; Seok-Beom Kwon
Journal:  Korean J Radiol       Date:  2012-04-17       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.